Logo image of ATOS

ATOSSA THERAPEUTICS INC (ATOS) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:ATOS - US04962H5063 - Common Stock

0.603 USD
-0.01 (-1.95%)
Last: 1/20/2026, 8:00:01 PM
0.599 USD
0 (-0.66%)
After Hours: 1/20/2026, 8:00:01 PM
Fundamental Rating

3

ATOS gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 525 industry peers in the Biotechnology industry. ATOS has a great financial health rating, but its profitability evaluates not so good. ATOS does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

  • In the past year ATOS has reported negative net income.
  • In the past year ATOS has reported a negative cash flow from operations.
  • In the past 5 years ATOS always reported negative net income.
  • ATOS had a negative operating cash flow in each of the past 5 years.
ATOS Yearly Net Income VS EBIT VS OCF VS FCFATOS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -10M -20M -30M

1.2 Ratios

  • ATOS's Return On Assets of -52.02% is in line compared to the rest of the industry. ATOS outperforms 48.19% of its industry peers.
  • ATOS has a Return On Equity of -60.62%. This is in the better half of the industry: ATOS outperforms 61.33% of its industry peers.
Industry RankSector Rank
ROA -52.02%
ROE -60.62%
ROIC N/A
ROA(3y)-28.82%
ROA(5y)-30.64%
ROE(3y)-30.53%
ROE(5y)-37.72%
ROIC(3y)N/A
ROIC(5y)N/A
ATOS Yearly ROA, ROE, ROICATOS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50 -100 -150 -200 -250

1.3 Margins

  • ATOS does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ATOS Yearly Profit, Operating, Gross MarginsATOS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024

More info and screens

7

2. Health

2.1 Basic Checks

  • ATOS has more shares outstanding than it did 1 year ago.
  • The number of shares outstanding for ATOS has been increased compared to 5 years ago.
  • There is no outstanding debt for ATOS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
ATOS Yearly Shares OutstandingATOS Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M
ATOS Yearly Total Debt VS Total AssetsATOS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M

2.2 Solvency

  • ATOS has an Altman-Z score of -0.89. This is a bad value and indicates that ATOS is not financially healthy and even has some risk of bankruptcy.
  • ATOS has a Altman-Z score of -0.89. This is comparable to the rest of the industry: ATOS outperforms 57.33% of its industry peers.
  • ATOS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -0.89
ROIC/WACCN/A
WACCN/A
ATOS Yearly LT Debt VS Equity VS FCFATOS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M 100M

2.3 Liquidity

  • A Current Ratio of 6.77 indicates that ATOS has no problem at all paying its short term obligations.
  • With a decent Current ratio value of 6.77, ATOS is doing good in the industry, outperforming 69.14% of the companies in the same industry.
  • A Quick Ratio of 6.77 indicates that ATOS has no problem at all paying its short term obligations.
  • The Quick ratio of ATOS (6.77) is better than 69.33% of its industry peers.
Industry RankSector Rank
Current Ratio 6.77
Quick Ratio 6.77
ATOS Yearly Current Assets VS Current LiabilitesATOS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M

More info and screens

1

3. Growth

3.1 Past

  • ATOS shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 4.00%.
EPS 1Y (TTM)4%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-16.67%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • The Earnings Per Share is expected to grow by 13.73% on average over the next years. This is quite good.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-21.43%
EPS Next 2Y-18%
EPS Next 3Y-16.44%
EPS Next 5Y13.73%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ATOS Yearly Revenue VS EstimatesATOS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2028 2029 2030 2031 2032 200M 400M 600M 800M
ATOS Yearly EPS VS EstimatesATOS Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -20 -40 -60 -80

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

  • ATOS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Also next year ATOS is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ATOS Price Earnings VS Forward Price EarningsATOS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ATOS Per share dataATOS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2

4.3 Compensation for Growth

  • ATOS's earnings are expected to decrease with -16.44% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-18%
EPS Next 3Y-16.44%

More info and screens

0

5. Dividend

5.1 Amount

  • ATOS does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

ATOSSA THERAPEUTICS INC

NASDAQ:ATOS (1/20/2026, 8:00:01 PM)

After market: 0.599 0 (-0.66%)

0.603

-0.01 (-1.95%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-12
Earnings (Next)03-23
Inst Owners19.46%
Inst Owner Change0%
Ins Owners0.04%
Ins Owner Change0%
Market Cap77.89M
Revenue(TTM)N/A
Net Income(TTM)-30.18M
Analysts82
Price Target5.87 (873.47%)
Short Float %1.79%
Short Ratio1.85
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-11.14%
Min EPS beat(2)-19.35%
Max EPS beat(2)-2.94%
EPS beat(4)2
Avg EPS beat(4)3.45%
Min EPS beat(4)-19.35%
Max EPS beat(4)22.6%
EPS beat(8)4
Avg EPS beat(8)-0.71%
EPS beat(12)7
Avg EPS beat(12)1.15%
EPS beat(16)11
Avg EPS beat(16)4.28%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)1.1%
PT rev (3m)2.22%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-2.57%
EPS NY rev (1m)0%
EPS NY rev (3m)-2.04%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 1.56
P/tB 1.56
EV/EBITDA N/A
EPS(TTM)-0.24
EYN/A
EPS(NY)-0.29
Fwd EYN/A
FCF(TTM)-0.2
FCFYN/A
OCF(TTM)-0.2
OCFYN/A
SpS0
BVpS0.39
TBVpS0.39
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -52.02%
ROE -60.62%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-28.82%
ROA(5y)-30.64%
ROE(3y)-30.53%
ROE(5y)-37.72%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 78.95%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 6.77
Quick Ratio 6.77
Altman-Z -0.89
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)157.54%
Cap/Depr(5y)108.53%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)4%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-16.67%
EPS Next Y-21.43%
EPS Next 2Y-18%
EPS Next 3Y-16.44%
EPS Next 5Y13.73%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-11.38%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-31.93%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-31.99%
OCF growth 3YN/A
OCF growth 5YN/A

ATOSSA THERAPEUTICS INC / ATOS FAQ

What is the fundamental rating for ATOS stock?

ChartMill assigns a fundamental rating of 3 / 10 to ATOS.


Can you provide the valuation status for ATOSSA THERAPEUTICS INC?

ChartMill assigns a valuation rating of 0 / 10 to ATOSSA THERAPEUTICS INC (ATOS). This can be considered as Overvalued.


Can you provide the profitability details for ATOSSA THERAPEUTICS INC?

ATOSSA THERAPEUTICS INC (ATOS) has a profitability rating of 1 / 10.


How financially healthy is ATOSSA THERAPEUTICS INC?

The financial health rating of ATOSSA THERAPEUTICS INC (ATOS) is 7 / 10.